These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15637534)

  • 21. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ; Romagosa R; Vincek V
    J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
    [No Abstract]   [Full Text] [Related]  

  • 22. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C.
    Schmidt F; Janssen G; Martin G; Lorenz R; Loeschke K; Soyka M; Folwaczny C; Schaefer M
    Aliment Pharmacol Ther; 2009 Nov; 30(10):1049-59. PubMed ID: 19691667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cutaneous reactions induced by pegylated-interferon plus ribavirin combination therapy in a patient with chronic hepatitis C].
    Enjoji M; Dainichi T; Gondo H; Urabe K
    Fukuoka Igaku Zasshi; 2007 Sep; 98(9):353-6. PubMed ID: 17974079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
    Meyer-Wyss B; Rich P; Egger H; Helbling B; Müllhaupt B; Rammert C; Gonvers JJ; Oneta C; Criblez D; Rossi L; Borovicka J; Meyenberger C; Arn M; Renner EL;
    J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. r-Interferon alfa-2b/ribavirin combined therapy followed by low-dose r-interferon alfa-2b in chronic hepatitis C interferon nonresponders.
    Perasso A; Testino G; Ansaldi F; Venturino V; Icardi GC
    Hepatology; 1999 Jan; 29(1):297-8. PubMed ID: 9935339
    [No Abstract]   [Full Text] [Related]  

  • 27. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
    Glue P; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S; Clement RP
    Hepatology; 2000 Sep; 32(3):647-53. PubMed ID: 10960463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience.
    Schvarcz R; Ando Y; Sönnerborg A; Weiland O
    J Hepatol; 1995; 23 Suppl 2():17-21. PubMed ID: 8720289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
    Maddrey WC
    Semin Liver Dis; 1999; 19 Suppl 1():67-75. PubMed ID: 10349694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C.
    Raison CL; Broadwell SD; Borisov AS; Manatunga AK; Capuron L; Woolwine BJ; Jacobson IM; Nemeroff CB; Miller AH
    Brain Behav Immun; 2005 Jan; 19(1):23-7. PubMed ID: 15581735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pegylated interferon: new preparation. Chronic hepatitis C: advantageous for some patients, but more data needed.
    Prescrire Int; 2003 Dec; 12(68):206-10. PubMed ID: 14986684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.
    Schaefer M; Hinzpeter A; Mohmand A; Janssen G; Pich M; Schwaiger M; Sarkar R; Friebe A; Heinz A; Kluschke M; Ziemer M; Gutsche J; Weich V; Halangk J; Berg T
    Hepatology; 2007 Oct; 46(4):991-8. PubMed ID: 17668880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hashimoto encephalopathy with pegylated interferon alfa-2b and ribavirin.
    Deutsch M; Koskinas J; Tzannos K; Vassilopoulos D; Mailis A; Tolis G; Hadziyannis S
    Ann Pharmacother; 2005 Oct; 39(10):1745-8. PubMed ID: 16159996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Why is there a poor response to combined therapy with interferon alfa 2b and ribavirin in patients with chronic hepatitis C?].
    Stránský J; Rýzlová M; Stríteský J; Nĕmecek V
    Cas Lek Cesk; 2002 Jun; 141(11):351-4. PubMed ID: 12099059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy.
    Narayanan Menon KV; Poterucha JJ; El-Amin OM; Burgart LJ; Kremers WK; Rosen CB; Wiesner RH; Charlton M
    Liver Transpl; 2002 Jul; 8(7):623-9. PubMed ID: 12089717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.
    Zeuzem S; Hultcrantz R; Bourliere M; Goeser T; Marcellin P; Sanchez-Tapias J; Sarrazin C; Harvey J; Brass C; Albrecht J
    J Hepatol; 2004 Jun; 40(6):993-9. PubMed ID: 15158341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
    Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
    Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Combined interferon-alfa-2b and ribavirin therapy in patients with recurrent chronic hepatitis c after liver transplantation].
    Lengyel G; Kóbori L; Fehérvári I; Nemes B; Görög D; Patonai A; Sárváry E; Varga M; Perner F; Fehér J
    Orv Hetil; 2003 Nov; 144(48):2367-70. PubMed ID: 14753031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Interferon-related retinopathy in a man with chronic hepatitis C].
    Viennet A; Glatre F; Bacin F
    J Fr Ophtalmol; 2009 Sep; 32(7):505-10. PubMed ID: 19592135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
    Schaefer M; Schmidt F; Folwaczny C; Lorenz R; Martin G; Schindlbeck N; Heldwein W; Soyka M; Grunze H; Koenig A; Loeschke K
    Hepatology; 2003 Feb; 37(2):443-51. PubMed ID: 12540795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.